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Gene targets of mouse miR-709: 
regulation of distinct pools
Sneha Surendran1, Victoria N. Jideonwo1, Chris Merchun1, Miwon Ahn1, John Murray1, 
Jennifer Ryan2, Kenneth W. Dunn2, Janaiah Kota1 & Núria Morral1,3
MicroRNA (miRNA) are short non-coding RNA molecules that regulate multiple cellular processes, 
including development, cell differentiation, proliferation and death. Nevertheless, little is known 
on whether miRNA control the same gene networks in different tissues. miR-709 is an abundant 
miRNA expressed ubiquitously. Through transcriptome analysis, we have identified targets of miR-
709 in hepatocytes. miR-709 represses genes implicated in cytoskeleton organization, extracellular 
matrix attachment, and fatty acid metabolism. Remarkably, none of the previously identified targets 
in non-hepatic tissues are silenced by miR-709 in hepatocytes, even though several of these genes 
are abundantly expressed in liver. In addition, miR-709 is upregulated in hepatocellular carcinoma, 
suggesting it participates in the genetic reprogramming that takes place during cell division, when 
cytoskeleton remodeling requires substantial changes in gene expression. In summary, the present 
study shows that miR-709 does not repress the same pool of genes in separate cell types. These results 
underscore the need for validating gene targets in every tissue a miRNA is expressed.
MicroRNAs (miRNAs) are a class of small (~19–23 nt) non-coding RNAs that are widely expressed in plants, 
animals, and some viruses. It has been estimated that the human genome encodes over 2,400 miRNAs1, which 
regulate about 60% of mammalian genes2. Mammalian miRNAs can repress their targets through either protein 
translation inhibition or transcript destabilization (the predominant mechanism)3,4. An mRNA can be targeted by 
numerous miRNAs, and a single miRNA can target multiple mRNAs, which allows miRNAs to regulate multiple 
gene networks5. It is now widely accepted that miRNAs have important roles in regulating complex processes such 
as development6, cell cycle7, and metabolism8. Nevertheless, their role as regulators of gene expression is paradox-
ical. On one side, many miRNAs are highly conserved (sometimes even between vertebrates and invertebrates), 
which suggests functional importance9. On the other, deletion of individual miRNA often does not result in any 
obvious defects, implying that miRNAs are dispensable10. The view that is emerging from these studies is that, 
unlike transcription factors, most miRNA are not master regulators of gene expression11. Instead, miRNAs are 
fine tuners of transcription, contributing to set the mean level of expression of a gene, and buffering variations in 
expression due to environmental changes12. Thus, miRNAs confer robustness to transcriptional programs during 
transition from one developmental stage to another or during cell differentiation processes13.
miR-709 is an abundant miRNA expressed in multiple mouse tissues, including brain, thymus, heart, lung, 
liver, spleen, kidney, adipose tissue, and testes14–17. miR-709 is embedded in intron 8 of the Regulatory Factor X1 
(Rfx1) gene, a member of the winged-helix subfamily of helix-turn-helix transcription factors with activation as 
well as repression activity18. Like miR-709, Rfx1 is ubiquitously expressed19. A few studies have underscored the 
role of miR-709 in response to cellular stress and/or cell proliferation processes. In a mouse model of injury to 
the peripheral nervous system (PNS), miR-709 was found upregulated and shown to bind to the mRNA of tran-
scription factors Egr2, c-Jun, and Sox-2, key mediators of dedifferentiation and myelination/demyelination20. In 
mouse testis, miR-709 controls expression of Brother Of the Regulator of Imprinted Sites (BORIS)14. BORIS is an 
important regulator of DNA methylation and imprinting, and controls epigenetic reprogramming during differen-
tiation of germ cells21. In adipocytes, miR-709 plays a role on differentiation by targeting glycogen synthase kinase 
3β (GSK3β )15. Finally, miR-709 has been shown to inhibit Notch1-induced T cell acute lymphoblastic leukemia 
(T-ALL) by targeting the oncogene c-Myc, Akt and Ras-GRF122.
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Every tissue possesses a distinctive transcriptome and miRNA signature. miRNAs expressed in multiple tissues 
would be predicted to bind to and regulate the same genes in these tissues, as long as the mRNAs were part of the 
tissue’s transcriptome. Currently, it is not known whether miR-709, a ubiquitous miRNA, regulates the same genes 
in different tissues. Here we have used a comprehensive approach to identify liver targets of miR-709, with special 
emphasis on analysis of previously validated targets in non-hepatic tissues.
Results and Discussion
miR-709 is highly abundant in mouse liver. It has been reported that only the most abundant miR-
NAs suppress their target genes, and about 60% are not active23. To identify miRNAs expressed in liver, miRNA 
profiles were obtained. Based on signal intensity, mmu-miR-709 (miR-709) is expressed at high levels in this 
tissue, at approximately one-fourth of the most abundant miRNA, miR-122, and ~2-fold higher than let-7a 
(Supplementary Table 1). Computational analysis of predicted targets using miRanda24 and miRWalk25 suggested 
that miR-709 gene targets are associated with cytoskeleton functions.
miR-709 induces transcriptional silencing of cytoskeleton genes. Based on information available 
from the miRBase, the 3p strand of miR-709 is used for silencing (http://www.mirbase.org). We used luciferase 
reporter plasmids containing the complementary sequence to miR-709 (tough decoys), to confirm that in pri-
mary hepatocytes the 3p strand of miR-709 is used to repress its targets (Fig. 1A). The degree of luciferase repres-
sion was ~3-fold below the level observed with a tough decoy containing a target site for miR-122, the most 
abundant miRNA in liver, which is consistent with the amount of miR-709 relative to miR-122 (Supplementary 
Table 1). This indicates that miR-709 is expressed in hepatocytes and that the 3p strand is used for gene silencing.
Figure 1. Targets of miR-709. (A) Primary hepatocytes were transfected with a tough decoy (TuD) containing 
8 copies of the sequence complementary to the 3′ strand of miR-709 (shown in red; the sequence in black shows 
the mature 3′ strand of miR-709); TuD122: TuD for miR-122, used as positive control; psiCK2: psiCHECK2 
plasmid without miRNA binding sites. Values represent mean ± SD (n = 3). The experiment was repeated in a 
separate hepatocyte isolation, with similar results. (B) Mouse primary hepatocytes were transfected with miR-
709 or Cel-239b and harvested 24 hour later. Analysis of CD36, Acox2, Rab11b, Pfkl, Pctp, Gck and Ces1g, was 
performed by qRT-PCR. TATA binding protein (TBP) was used as normalizer gene. The fold change relative to 
Cel-239b for each gene is plotted. Values represent mean ± SD (n = 3–4). (C) Western blot analysis of proteins. 
Primary hepatocytes were transfected with miR-709 or Cel-239b and cells were harvested 48 hours or 96 hours 
later. Bands on blot were quantified by densitometry using ImageJ v1.48s, and results were normalized to 
control protein (Cyclophillin-40 or ß-actin). Values represent mean ± SD (n = 3). The experiment was repeated 
in a separate hepatocyte isolation, with similar results. *p < 0.05 and **p < 0.01, miR-709 vs Cel-239b.
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It is widely accepted that mammalian miRNAs repress their targets mostly through mRNA destabilization 
rather than translation inhibition4,26. mRNA degradation accounts for 66 to 90% of miRNA-mediated regulation27. 
Therefore, we proceeded to identify miR-709 targets by transcriptome analysis. Mouse primary hepatocytes were 
transfected with miR-709 mimic or a control miRNA, Cel-239b, and harvested 24 hour later. This resulted in a 
3.8-fold increase in cytoplasmic levels of miR-709 (Supplementary Fig. 1). Gene expression profiles were then 
generated using Affymetrix mRNA microarrays. Hierarchical cluster of the 100 genes with the lowest p-value 
indicated that all the samples within a treatment group cluster together (Supplementary Fig. 2). A total of 556 genes 
were downregulated and 848 were increased in miR-709-treated cells compared to Cel-239b (p < 0.01). Among 
genes downregulated, 36 were significantly decreased > 2-fold in the miR-709 group compared to Cel-239b-treated 
control cells (Table 1), while only 4 were upregulated > 2-fold (Table 2). Based on DAVID bioinformatics analysis28, 
the 36 genes are involved in lipid synthesis and transport (Ces1, Pctp, Daglb, Cyp20a1), cytoskeleton organization 
and endosomal recycling (Rab11b, Dync1li1, Acta2, M6prbp1, Myo1d, Tagln, Cnn1, Sema6a) and cell adhesion 
(Timp3, Nid1, Thbs1, Krt19, Mpzl2) (Table 1).
We then analyzed if there was any correlation between the extent of downregulation with target prediction 
using 3 databases: miRanda24, miRWalk25, and DIANAmT29. As many as 21 of the 36 genes downregulated > 2-fold 
(58.3%) were predicted targets by all 3 databases, while the percentage dropped to 32.6% (170 out of 520) for genes 
downregulated < 2-fold, and to 13.2% (112 out of 848) for upregulated genes. This suggests that there is a correla-
tion between target prediction and fold-level downregulation, with the highest representation of predicted targets 
within the pool of genes that are downregulated above 2-fold. However, there was no correlation in the number of 
predicted miR-709 binding sites in the mRNA and the degree of downregulation: an average of 1.87 ± 1.04 binding 
Gene symbol Gene name Cellular role Fold change p-value
Tspan31 Tetraspanin 31 Cell adhesion − 5.27 1.8E-06
Rab11b Ras-related protein Endosomal recycling − 4.18 6.5E-06
Cyp20a1 Cytochrome P450, Family 20, Subfamily A, Polypeptide 1 Lipid metabolism, detoxification − 3.76 1.2E-07
Dync1li1 Dynein, cytoplasmic 1, light intermediate chain 1 Cytoskeleton organization − 3.40 2.3E-07
Bpnt1 3'(2'), 5'-bisphosphate nucleotidase 1 Cytoplasmic, nucleotide hydrolysis − 3.28 9.3E-09
Mmachc Methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria Vitamin B transport − 3.27 1.5E-05
Ces1 Carboxylesterase 1 Lipid metabolism − 3.22 1.7E-06
Timp3 Tissue inhibitor of metalloproteinases 3 Cell adhesion − 3.20 4.6E-05
Pctp Phosphatidylcholine transfer protein Lipid metabolism − 3.19 6.2E-07
Nid1 Nidogen 1 Cell adhesion − 3.03 2.7E-06
Slc35e1 Solute carrier family 35, member E1 Unknown function − 2.95 3.7E-09
Mare Alpha globin regulatory element containing gene Unknown function − 2.75 7.0E-08
D13Wsu177e (Nop16) DNA segment, Chr 13, Wayne State University 177, expressed Cell proliferation − 2.71 1.7E-08
Thbs1 Thrombospondin 1 Cell adhesion − 2.67 2.1E-06
Lrrc58 Leucine rich repeat containing 58 Unknown function − 2.53 6.2E-07
Acta2 Actin, alpha 2, smooth muscle, aorta Cytoskeleton organization − 2.52 1.4E-05
M6prbp1 Mannose-6-phosphate receptor binding protein 1 Endosomal recycling − 2.50 1.7E-06
Atrn Attractin Cell membrane (inflammatory response) − 2.46 4.7E-06
Mpzl2 Myelin protein zero-like 2 Cell adhesion − 2.41 4.1E-06
Tagln Transgelin Cytoskeleton organization − 2.36 6.6E-06
Cnn1 Calponin 1 Cytoskeleton organization − 2.36 4.0E-05
Krt19 Keratin 19 Cytoskeleton organization; Cell adhesion − 2.35 2.9E-03
Myo1d Myosin ID Cytoskeleton organization; Endosomal recycling − 2.31 1.5E-07
Cyb5d2 Cytochrome b5 domain containing 2 Lipid metabolism, detoxification − 2.29 1.1E-06
Actc1 Actin, alpha, cardiac muscle 1 Cytoskeleton organization − 2.29 1.3E-05
Pfas Phosphoribosylformylglycinamidine synthase Purine metabolism − 2.27 1.1E-08
Ggcx Gamma-glutamyl carboxylase Cytoplasmic, peptidyl-glutamic acid carboxylation − 2.20 7.5E-05
Ccnyl1 Cyclin Y-like 1 Cell proliferation − 2.17 1.0E-05
Amt Aminomethyltransferase Mitochondrion − 2.16 2.0E-04
BC057893 cDNA sequence BC057893 Unknown function − 2.12 3.3E-06
Gpr155 G protein-coupled receptor 155 Cell membrane, signaling − 2.05 1.7E-04
Daglb Diacylglycerol lipase, beta Lipid metabolism − 2.05 2.7E-06
Sema6a Sema domain, transmembrane domain (TM), and cytoplasmic Cytoskeleton organization − 2.04 9.4E-05
Fnip2 Folliculin interacting protein 2 Cytoplasmic, tumor suppressor − 2.01 3.9E-04
Slc7a1 Solute carrier family 7 (cationic amino acid transporter Basic amino acid transport − 2.01 1.6E-06
Mobkl2a MOB1, Mps One Binder kinase activator-like 2A Cell proliferation − 2.00 2.3E-05
Table 1.  Genes significantly downregulated >2-fold in miR-709-transfected primary hepatocytes 
(p < 0.01).
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sites for the 36 genes downregulated > 2-fold, versus 1.79 ± 1.35 for a subgroup of 36 genes downregulated < 2-fold 
(− 1.23 to − 1.25-fold), p = 0.82. Thus, factors different from the number of predicted binding sites in the mRNA 
are more likely to influence the extent of repression.
To validate the microarray results, several genes were analyzed by quantitative real time RT-PCR (qPCR), 
including Cd36 (+ 1.8-fold), Acyl-Coenzyme Oxidase 2 (Acox2, + 1.6-fold), Glucokinase (Gck, + 1.5-fold), Rab11b 
(− 4.1-fold), Ces1g (− 3.2-fold), Pctp (− 3.1-fold), Phosphofructokinase (Pfkl, − 1.2-fold), and cytochrome P450, 
family 2, subfamily c, polypeptide 29 (Cyp2c29, + 5.59-fold). Identical trends to those observed in the microarray 
analysis were observed (Fig. 1B, and Supplementary Fig. 3A). We then assessed whether mRNA downregulation 
resulted in changes in protein. Interestingly, no changes in protein levels were observed even after 4 days for genes 
that showed less than 2-fold difference in the microarray, such as Gck (+ 1.5-fold), Slc27a1 (or Fatp1, − 1.9-fold), 
and Low-density Lipoprotein Receptor (Ldlr, − 1.2-fold). Insulin Receptor (Insr, − 1.1-fold, p = 0.42) was analyzed 
as a negative control (Fig. 1C, and Supplementary Fig. 3B). Protein changes did not correlate with target prediction 
in this group: Slc27a1 (Fatp1) and Gck were predicted miR-709 targets, while Ldlr was not. Insr is a predicted target, 
and neither the mRNA or protein were changed by miR-709. Instead, genes whose mRNAs were downregulated 
multiple fold, such as Rab11b (− 4.1-fold), Dync1li1 (− 3.4-fold), and Timp3 (− 3.2-fold), had significant decreases 
in protein levels (90%, 70% and 47% decrease, respectively; Fig. 1C). All three are predicted targets of miR-709.
To verify that the genes identified by microarray are direct targets of miR-709, we looked for predicted miR-
709 binding sites on the 3′ UTR of three target genes using the miRanda database24. Rab11b, Pctp and Ces1g had 
3, 4, and 1 binding sites, respectively. Plasmids containing a portion of the 3′ UTR of these genes, with or without 
predicted miR-709 binding sites (Fig. 2A), were generated and used in luciferase assays. As expected, lower levels 
of Renilla luciferase were observed with the constructs containing binding sites for miR-709 (p.Rab11b, p.Pctp 
and p.Ces1g), compared to constructs that had a fragment of the 3′ UTR without the miR-709 binding sequence 
(p.NC-Rab11b, p.NC-Pctp, and p.NC-Ces1g) (Fig. 2B). Furthermore, luciferase was lower only when miR-709 
mimic –but not Cel-239b– was used. These data indicate that Rab11b, Pctp, and Ces1g are direct targets of miR-
709, supporting the microarray results.
miR-709 regulates a distinct set of genes in liver. Given that miR-709 is a ubiquitously expressed 
miRNA, we then questioned whether it regulates the same genes in separate tissues. Eight genes have been pre-
viously shown to be validated targets of miR-709 in non-hepatic tissues (Table 3). Except for Gsk3β , which is 
repressed at the protein level only, all other genes are downregulated through a decrease in the amount of tran-
script14,15,20,22. Remarkably, none of these genes were considerably reduced by miR-709 in hepatocytes (Table 3). 
Only one was slightly increased (Egr2; + 1.13), while a second was mildly decreased (Akt1; − 1.18-fold), without 
leading to changes in protein (Fig. 3). Likewise, miR-709 had no impact on Gsk3β protein, a target in adipocytes 
(Fig. 3).
A miRNA that is expressed ubiquitously would be predicted to bind to and repress the same genes in different 
tissues, provided that the target genes were expressed in these tissues. Nevertheless, our data indicates that this is 
not necessarily the case. Indeed, half of the previously described miR-709 targets are abundantly expressed in liver 
[Jun, Gsk3β, Myc, Akt1; Table 3. As reference, albumin (Alb), fatty acid synthase (Fasn) and LDL receptor (Ldlr) 
have log2 signals of 13.5, 9.1 and 10.5, respectively]. Akt1 and Gsk3β , in particular, are important molecules in the 
insulin signaling pathway, regulating energy metabolism, glycogen synthesis, cell survival and cellular prolifera-
tion30. Neither one was significantly silenced by miR-709 in this tissue. Similarly, genes expressed at extremely low 
levels in liver, were not affected by miR-709 [Egr2, Sox-2, Ctcfl, Ras-GRF1; Table 3. Genes that are not normally 
expressed in hepatocytes such as gastric inhibitory polypeptide (Gip; expressed in intestinal cells) and glucagon 
(Gcg; pancreas-specific), have log2 probe signals of 4.8 and 3.4, respectively].
To validate the newly identified miR-709 targets in other cell types, 3T3-L1 fibroblasts and C2C12 myoblasts 
were transfected with miR-709 mimic (Fig. 4). As observed in primary hepatocytes, Rab11b and Dync1li1 were 
significantly downregulated in these cells. However, Akt and Gsk3β were not repressed, as had been observed 
in primary hepatocytes. miR-709 levels are lower in T cell acute lymphoblastic leukemia and during adipocyte 
differentiation, and this decrease is needed for the oncogenic and the differentiation process to occur15,22. Overall, 
the data suggest that some miR-709 gene targets may be regulated by this miRNA in multiple tissues (Rab11b, 
Dync1li1). However, other targets, including Akt and Gsk3β, may only be regulated by miR-709 in specific tissues 
and/or during oncogenic/developmental conditions. Thus, despite being a ubiquitous miRNA, miR-709 appears 
to control different gene networks in specific cellular processes and tissues, influencing distinct genetic programs.
miR-709 is upregulated in hepatocellular carcinoma. Multiple studies have provided evidence that 
most miRNAs exert only a mild repression on their targets12. This has prompted the notion that a general func-
tion of miRNAs is to tune and/or buffer expression of their targets, setting their mean level of expression and 
minimizing variance upon environmental changes. miR-709 is upregulated in response to cellular stress or tissue 
Gene symbol Gene name Cellular role Fold change p-value
Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29 Metabolism of foreign compounds + 5.59 5.8E-09
A1cf APOBEC1 complementation factor Apolipoprotein B metabolism + 2.05 2.7E-06
Taf2 TAF2 RNA polymerase II, TATA box binding protein (TBP)-a Transcription initiation + 2.04 9.1E-07
Hgd homogentisate 1, 2-dioxygenase Catabolism of amino acids + 2.04 1.2E-05
Table 2.  Genes significantly upregulated >2-fold in miR-709-transfected primary hepatocytes (p < 0.01).
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injury, and is involved in the genetic reprogramming that follows14,15,20. In peripheral nerve system (PNS) injury, 
miR-709 and miR-138 have opposing roles. miR-709 increases, repressing target gene expression, and miR-138 
decreases, de-repressing expression20. The combined action of the miRNAs determines the end level of their 
targets: Egr2 (decreases in injury), Sox-2 (increases) and c-Jun (increases)20. Cytoskeleton reorganization is a 
distinctive feature of proliferative states such as hepatocellular carcinoma (HCC). In addition, a hallmark of HCC 
is the presence of genetic reprogramming towards a dedifferentiated state, during which liver-specific functions 
are shutdown31. We questioned whether miR-709 would be dysregulated in this process, as occurs in PNS injury20. 
Figure 2. Pctp, Ces1g, and Rab11b are directly repressed by miR-709. (A) miR-709 binding sites in the 
3′ UTR of Pctp, Ces1g and Rab11b mRNA. The binding sequence is shown in red, and the seed sequence is 
underlined. (B) Primary hepatocytes were transfected with miR-709 or Cel-239b, and plasmids containing 
the 3′ UTR of Pctp, Ces1g, or Rab11b. Twenty-four hours later, dual-luciferase assays were performed. Renilla 
luciferase activity was normalized to firefly luciferase expressed from the same plasmid. Values represent 
mean ± SD (n = 3). The experiment was repeated in a separate hepatocyte isolation, with similar results; 
p-values (**p < 0.01) are relative to cells treated with the same plasmid plus Cel-239b; p.709: plasmid containing 
the sequence perfectly complementary to miR-709-3p strand; p.Pc, p.Ce and p.Ra: plasmids containing a 
fragment of the 3′ UTR with miR-709 binding sites of Pctp, Ces1g and Rab11b, respectively; p.NC-Pc, p.NC-Ce 
and p.NC-Ra: plasmids with a fragment of the 3′ UTR without miR-709 binding sites.
Gene symbol Tissue Ref.
Primary hepatocytes
Mean Cel*
Mean 
709*
Fold 
change p-value
Egr2 Sciatic nerve 20 4.65 4.83 + 1.13 2.6E-02
Sox-2 Sciatic nerve 20 3.77 3.78 + 1.01 9.2E-01
Jun Sciatic nerve 20 8.84 8.77 − 1.05 3.1E-01
Ctcfl (BORIS) Testes 14 4.19 4.15 − 1.03 6.8E-01
Gsk3β Adipocytes 15 8.82 8.67 − 1.11 7.5E-02
Myc T cell acute lymphoblastic leukemia 22 10.02 9.99 − 1.02 6.5E-01
Ras-GRF1 T cell acute lymphoblastic leukemia 22 4.01 3.93 − 1.06 1.0E-01
Akt1 T cell acute lymphoblastic leukemia 22 9.41 9.17 − 1.18 1.8E-03
Table 3.  Previously validated miR-709 gene targets are not considerably modified in hepatocytes. *Log2 
mean signal.
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Remarkably, levels of mature miR-709 were significantly upregulated (5.3-fold) in liver tumors (Fig. 5A), indi-
cating that this miRNA is associated with the genetic reprogramming that takes place in HCC. Consistent with 
the dedifferentiated state31, proteins involved in liver-specific functions, such as carnitine palmitoyl transferase 
2 (CPT2) and mitochondrially encoded cytochrome c oxidase I (MT-CO1) (enzymes of the fatty acid oxidation 
pathway) were downregulated in tumors (Fig. 5B). In contrast, the cytoskeleton protein α -tubulin, was robustly 
upregulated, as expected in cells that are actively dividing. Similarly, miR-709 targets that are involved in cytoskel-
eton function and attachment to the extracellular matrix, Rab11b, Dync1li1 and Timp3, were upregulated in tum-
ors relative to adjacent non-tumor liver and livers from control mice (Fig. 5B). These data suggest that the overall 
level of expression of these genes is influenced by the simultaneous action of multiple miRNA, some of which 
increase (like miR-709), while others decrease in HCC, as described in PNS injury20.
Conclusions
In this study we have shown that the mRNAs of hundreds of genes are changed upon increasing miR-709 in 
hepatocytes. Nevertheless, the majority of the changes are lower than 2-fold, and do not necessarily lead to signif-
icant changes in protein levels. It is possible that repression of a number of genes occurs at the translational level 
instead of the mRNA, and additional genes from those identified through our microarray might be regulated by 
miR-709. In hepatocytes (and most probably in other cell types) miR-709 regulates structural and cell adhesion 
target genes, where it is likely to contribute to maintain the appropriate level of its targets during cell proliferation, 
thereby tuning/buffering gene expression. Increasing cytoplasmic levels of miR-709 has no impact on cell viability 
or proliferation (Supplementary Fig. 4). Despite its ubiquitous expression, miR-709 has distinctive targets during 
particular cellular processes, which underscores the complexity of gene regulation. Multiple factors can influence 
the dynamics of expression of any given gene, in addition to miRNAs. Transcription factors, mRNA tertiary 
structure, RNA conformation, and the presence of RNA binding proteins13, can influence the overall level of an 
mRNA. It is likely that one of these elements has a prominent role in determining the levels of a transcript in a 
specific tissue, while being less important in another. Thus, a miRNA may be essential in regulating an mRNA in 
one tissue, but not be critical in a different one. Overall, our data suggest that understanding the biological function 
of a miRNA may require carrying out studies in each tissue in which it is expressed.
Materials and Methods
Animals. All animal studies were in accordance with the National Institutes of Health guidelines and were 
approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee. Four 
12-week old, male C57BLKS/J mice were used to study miRNA expression profiles. Male C57BL/6J mice (24 to 
30 g) were used for isolation of primary hepatocytes. Mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME), and allowed to acclimate for at least a week before experimentation. A standard 12 h light/12 h 
Figure 3. miR-709 does not repress Akt and GSK3β in primary hepatocytes. (A) Mouse primary hepatocytes 
were transfected with miR-709 or Cel-239b and harvested 24, 48, 72 and 96 hour later. Akt, GSK3β , Rab11b 
and Cyclophillin-40 were analyzed by Western blot analysis. (B) Previously validated miR-709 binding sites 
in Akt1 and Gsk3β15,22. Gsk3α does not have binding sites for miR-709 (miRanda database24). (C) Bands from 
the 96 hour time point were quantified by densitometry using ImageJ v1.48s, and results were normalized to 
the loading control (Cyclophillin-40); values represent mean ± SD; data from 2 independent experiments were 
averaged (total of 6 replicates per group); **p < 0.01.
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dark cycle (7 AM/7 PM) was maintained throughout the experiments. Mice were fed rodent chow ad libitum and 
allowed free access of water.
The mouse model of hepatocellular carcinoma has been previously described32. Briefly, LapMyc mice express 
the c-Myc oncogene conditionally regulated by the Tet-Off system. The tetracycline-transactivator (tTA) protein 
is driven by the liver-specific promoter Liver Activator Protein (LAP), and the c-Myc gene (in the Y chromosome) 
has a tetracycline response element. In the absence of doxycycline, tTA can bind to the response element and cause 
c-Myc expression in male mice, inducing HCC. Expression of c-Myc was induced at 4 weeks of age and animals 
were euthanized at 14 weeks of age. Mice are maintained in the FVB strain. LapMyc female littermates, FVB wild 
type female and Myc-doxy male mice were used as negative controls.
Primary hepatocyte isolation and cell culture. Primary hepatocytes were isolated from C57BL/6J mice 
using a two-step collagenase procedure followed by Percoll gradient centrifugation (to separate primary hepato-
cytes from non-parenchyma cells), as previously described33. Cell viability was assessed by trypan blue staining 
exclusion (> 80% viability). Cells were seeded at a density of 4–6 × 105 cells per well or 35-mm dish in DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin/streptomycin (P/S), 3 nM insulin and 
1 nM dexamethasone. Cells were incubated at 37 °C, 5% CO2 in a humidified incubator and allowed to attach for 
4 hours. Media was then replaced with fresh media.
Hepa1c1c7 cells (American Type Culture Collection, Manassas, VA) were cultured in MEM-α supplemented 
with 10% FBS and 1% (v/v) penicillin/streptomycin (P/S). 3T3-L1 fibroblasts were cultured in DMEM supple-
mented with 10% bovine calf serum and 1% (v/v) P/S. C2C12 myoblasts were cultured in DMEM supplemented 
with 10% FBS and 1% (v/v) P/S. The 3T3-L1 fibroblast and C2C12 myoblast cell lines were kindly provided by 
Dr. Jeffrey Elmendorf.
Plasmid cloning. Construct p.miR-709 was generated by cloning an oligonucleotide with a sequence per-
fectly complementary to the 3′ strand of miR-709 (based on the sequence published in TargetScan), downstream 
of the renilla luciferase gene in psiCHECKTM-2 (Promega, Madison, WI). Tough decoys (TuDs) binding miR-709 
or miR-122 were generated by cloning 8 copies of the sequence complementary to the 3p strand of miR-709 or 
Figure 4. miR-709 does not repress Akt and GSK3β in 3T3-L1 fibroblasts and C2C12 myoblasts. 
(A) 3T3-L1 fibroblasts were cultured in 6-well plates and transfected with miR-709 or control Cel-239b. Cells 
were harvested after 48 and 96 hours. The densitometry analysis (ImageJ v1.48s) is shown on the right. Values 
represent mean ± SD (n = 3). (B) C2C12 myoblasts were transfected with miR-709 or control Cel-239b, and 
harvested after 48 hour. Akt, Gsk3, Dync1li1, and Rab11b were analyzed by Western blot. Values represent 
mean ± SD (n = 4); *p < 0.05, **p < 0.01.
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the 5p strand of miR-122, downstream from the luciferase gene in psiCHECKTM-2. The sequence inserted was 
synthesized with XhoI and NotI sites at the ends to facilitate cloning (GenScript, NJ, and Genewiz, NJ).
To confirm that Rab11b, Ces1g and Pctp are direct targets of miR-709, 150–300 base pairs of the 3′ UTR con-
taining the putative binding sites [microrna.org24], were cloned in the NotI-XhoI site of psiCHECKTM-2. Total 
mRNA from mouse liver was used to generate the cDNA (High Capacity cDNA reverse transcription kit, Applied 
Biosystems, Grand Island, NY) and the corresponding portion of the 3′ UTR of Rab11b, Ces1g and Pctp contain-
ing the putative miR-709 binding sites was amplified by PCR using primers with restriction sites for NotI-XhoI 
(Supplementary Table 2). PCR products were cloned into psiCHECKTM-2, generating plasmids p.Rab11b, p.Ces1g, 
and p.Pctp. In addition, a portion of the 3′ UTR without miR-709 binding sites was cloned into psiCHECKTM-2 
and used as negative controls (p.NC-Rab11b, p.NC-Ces1g, and p.NC-Pctp). Clones were sequenced prior to using 
them in luciferase assays.
Cell transfection. Mouse primary hepatocytes or Hepa1c1c7 cells were co-transfected with plasmids (1.5 μ g) 
and miR-709 or the control miRNA Cel-239b (1 μ g) (Dharmacon, Lafayette, CO), or with these miRNAs alone 
(1 μ g). Transfection was performed with Metafectene-Pro (Biontex, Munich, Germany), as described33. After 
overnight incubation, media was replaced with fresh media. For luciferase assays, cells were harvested 24 hours 
later and analyzed for luciferase activity using a Centro LB 960 Microplate Luminometer (Berthold Technologies, 
Oak Ridge, TN) and the dual-luciferase® reporter assay kit (Promega, Madison, WI). Renilla luciferase activity 
was normalized to firefly luciferase expressed from the same plasmid. 3T3-L1 fibroblasts and C2C12 myoblasts 
(4 × 105 cell/well) were cultured in 6-well plates and transfected with 1.5 and 1 μ g of miRNA, respectively. Cells 
were harvested after 48 or 96 hour.
Microarray analysis. miRNA array. The long (> 200 bp) and miRNA-enriched (< 200 bp) RNA fractions 
were isolated using the mirVana miRNA isolation kit (Ambion, Austin, TX). The miRNA-enriched RNA frac-
tion from normal, C57BLKS/J mouse liver was used to conduct miRNA chip analysis (LC Sciences, Houston, 
TX). The RNA from each sample was labeled and hybridized to each of four chips. Background was deter-
mined using a regression-based background mapping method. The regression was performed on 5% to 25% 
of the lowest intensity data points excluding blank spots. Raw data matrix was then subtracted from the back-
ground matrix. Normalization was carried out using a LOWESS (Locally-weighted Regression) method on the 
background-subtracted data. Transcripts were considered detectable if they met at least two conditions: signal 
intensity higher than 3xbackground standard deviation, and spot CV < 0.5. CV was calculated by (standard devi-
ation)/(signal intensity). A transcript was listed as detectable only if the signals from at least 50% of the repeating 
probes were above detection level. Data adjustment included data filtering, log2 transformation, and gene center-
ing and normalization. The data filtering removed miRNAs with (normalized) intensity values below a threshold 
value of 32 across all samples.
Figure 5. miR-709 expression in an animal model of hepatocellular carcinoma. (A) Mature miR-709 in 
LapMyc male (T: tumor and N-T: adjacent non-tumor tissue; n = 5) and LapMyc female (LM-f, negative 
control; n = 2) mouse livers were quantified by TaqMan assay. Values represent mean ± SD; *p < 0.05 between 
T and N-T groups. (B) Western blot analysis of MT-CO1, CPT2, IR-β , tubulin, and miR-709 targets (Rab11b, 
Dync1li1, Timp3) in tumor and control liver [adjacent non-tumor, LapMyc female and Myc male (doxycycline-
treated) mice].
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mRNA Affymetrix array. Four replicates for miR-709 and three replicates for Cel-239b were used. Total RNA was 
isolated from 1 × 106 cells 24 hours post-transfection using RNeasy Midi kit (Qiagen) following the manufacturer’s 
protocol. The quality of RNA was determined by Agilent 600 Nanobioanalyzer. mRNA microarray hybridization 
was performed by the Center for Medical Genomics, at Indiana University School of Medicine. Affymetrix mouse 
gene 1.0 ST arrays were used to compare expression of about 28,850 genes using one chip per replicate. Data was 
analyzed using a 1-way Anova using log2-transformed signals. Principal component analysis (PCA) and hierarchical 
clustering of the top 100 genes was done. Data generated from this microarray has been deposited at the NCBI 
GEO repository under accession number GSE63875.
qRT-PCR analysis. To analyze mRNA levels, qRT-PCR was carried out as described34 using the SYBR 
Green Qiagen One-Step reverse transcription-PCR kit (Qiagen, Valencia, CA) and the primer pairs described 
in Supplementary Table 2, in an ABI PRISM 7500 instrument (ABI, Foster City, CA). The TATA binding protein 
(Tbp) gene was used as loading control.
To quantify the level of mature miR-709, cDNA was generated from 10 ng of total RNA sample using the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Quantitative PCR was 
performed with TaqMan MicroRNA Assays (Applied Biosystems) specific for miR-709 (P/N 001644) and sno-202 
(P/N 001232).
Western blotting. Primary hepatocytes and liver tissues from the hepatocellular carcinoma animal model 
were lysed in RIPA buffer (Thermo Scientific, Rockford, IL) containing protease and phosphatase inhibitors 
(Roche, Indianapolis, IN). Protein concentration was determined using the BCA kit from Pierce (Rockford, IL). 
Proteins (20–30 μ g) were separated in 10% Tris-HCl SDS PAGE Criterion gel (Bio-Rad, Hercules, CA) and trans-
ferred to 0.2-μ m PVDF membrane (Bio-Rad). Antibodies were used to detect α -tubulin (Thermo Scientific, 
Rockford, IL); Timp3, FATP1 (ACSVL5), β -actin, IR-β (Santa Cruz Biotechnology, Dallas, TX); Dync1li1 
(GeneTex, San Antonio, TX); Cyclophillin-40, LDLR, MT-CO1 (Abcam, Cambridge, MA); Gck (Abgent, San 
Diego, CA); Rab11b, Akt and GSK3 (Cell Signaling, Danvers, MA); CPT2 antibody was a kind gift from Dr. 
Carina Prip-Buus (INSERM, U1016, Institut Cochin, Paris, France). HRP-conjugated secondary antibody 
was added and incubated at room temperature for 1 hour. Blots were developed with Pierce ECL kit (Thermo 
Scientific) and exposed to enhanced chemiluminescence (ECL) film (GE Healthcare, Piscataway, NJ).
Northern blotting. miRNA-enriched (200 bp) RNA fractions were isolated from ~100 mg of liver using 
mirVana RNA isolation kit according to the manufacturer’s instructions (Ambion, Austin, TX). Four μ g were 
separated on 15% TBE urea gels (Bio-Rad), transferred to Hybond-N membranes (GE Healthcare), and then 
UV-cross-linked using a Stratalinker 2400 (Stratagene, La Jolla, CA). 5S probe (100 pmol) was labeled with digox-
igenin (DIG) using a 2nd generation DIG oligonucleotide tailing kit (Roche, Indianapolis, IN). The probe was 
hybridized to membranes at 25 °C overnight in a hybridization oven after 2 hour of pre-hybridization at 60 °C. 
Three 2× SSC, 0.1% SDS washes were carried out for 10 min at room temperature followed by blocking and incu-
bating with antibody against DIG. The signal was developed using CSPD (Roche) according to the manufacturer’s 
instructions.
Statistical analysis. Data are presented as the arithmetic mean ± standard deviation (SD). Statistical dif-
ferences between miR-709 and Cel-239b-treated groups were calculated using the unpaired two-tailed Student’s 
t-test. A P value of less than 0.05 was considered statistically significant. As indicated in the figure legends, exper-
iments in primary hepatocytes were repeated in a separate hepatocyte isolation to confirm data.
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